Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.61 |
| ▸ | PDE3B | Q13370 | 8/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.61 |
| ▸ | PDE4A | P27815 | 9/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123040 | 0.82 | RAB9A (0.56) | PDE10APDE4BPDE3BPDE3ANPC1 | |
| SCHEMBL4763361 | 0.82 | RAB9A (0.56) | PDE10APDE4BPDE3BPDE3ANPC1 | |
| SCHEMBL30122891 | 0.82 | RAB9A (0.58) | PDE10APDE4BPDE3BPDE4ANPC1 | |
| SCHEMBL4766967 | 0.82 | RAB9A (0.58) | PDE10APDE4BPDE3BPDE4ANPC1 | |
| SCHEMBL4724444 | 0.81 | PDE10A (0.76) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL30123130 | 0.81 | PDE10A (0.76) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL24951298 | 0.81 | PDE10A (0.64) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL3271199 | 0.80 | PDE10A (0.79) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL30123112 | 0.80 | PDE10A (0.79) | PDE10APDE4BPDE3BPDE3APDE4A | |
| SCHEMBL3270154 | 0.80 | PDE10A (0.79) | PDE10APDE4BPDE3BPDE3APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| CN-115484938-A | Composition and use thereof | 博善人工智能剑桥有限公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-1979343-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | Pfizer Products Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007077490-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007077490-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | PDE10A 5/4885PDE4B 11/4885PDE3B 3/4885 |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PDE12, PDE10A, PDE7A | PDE10A 2/4885PDE4B 11/4885PDE3B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.